Synergy Pharmaceuticals Inc

Synergy Pharmaceuticals — Technical Presentation (May 2013)

20 slides from Synergy Pharmaceuticals's technical presentation, May 21, 2013

  1. Slide 1: Plecanatide Efficacious and Safe in Chronic Idiopathic Constipation: 951 Patient Trial

    Plecanatide, A Novel Guanylate Cyclase-C Receptor Agonist, is Efficacious and Safe in Patients with Chronic Idiopathic Constipation: Results from a 951 Patient, 12 Week, Multi-Center Trial Authors: Philip B. Miner*1, Ron Surowitz2, Ron Fogel3, William Koltun4, Douglas A. Drossman5, Michael Camilleri

  2. Slide 2: Plecanatide: Novel Approach to the Treatment of GI Disorders

    Plecanatide: Novel Approach to the Treatment of GI Disorders Analogue of uroguanylin- natural agonist of guanylate cyclase-C (GC-C) receptor Oral once-daily dosing Targets GC-C receptor in GI tract Essentially non-systemic Models normal physiology Plecanatide CIC Study

  3. Slide 3: Guanylate Cyclase-C Receptor Agonists Physiological Mechanism

    Guanylate Cyclase-C Receptor Agonists Physiological mechanism Cross section of the GI tract Activation of GC-C receptors stimulates synthesis of cyclic GMP, activating cystic fibrosis transmembrane conductance regulator (CFTR) Activated CFTR secretes Cl-, HCO3- and fluid into the intestinal lumen. S

  4. Slide 4: Plecanatide: A Novel Mechanism of Action to Treat Chronic Constipation and IBS-C

    Plecanatide: A Novel Mechanism of Action to Treat Chronic Constipation and IBS-C 16 mer peptide with 2 disulfide bonds Structurally similar to uroguanylin Plecanatide binding constant to human GC-C receptors is 8-fold higher than uroguanylin No systemic absorption up to single oral doses of 48.6 mg

  5. Slide 5: Protocol Design

    Protocol Design Aim: Determine safety, effectiveness and dose-response of Plecanatide in CIC patients Randomized, double–blind, placebo controlled, parallel group, stratified by gender, multicenter study Population: modified Rome III CIC criteria, including < 3 CSBMs/week Evaluation of Plecanatide d

  6. Slide 6: Key Protocol Inclusion/Exclusion

    Key Protocol Inclusion/Exclusion Inclusion Modified Rome III for CIC including < 3 CSBM during each week of 2 week pre-treatment Exclusion Rome III IBS-C diagnosis Previous major GI surgical history Recognized causes of constipation (opioids, iron supplements, hypothyroidism, etc.) Plecanatide CIC S

  7. Slide 7: Patient Populations Disposition

    Patient Populations Disposition n (%) Screened 1722 at 113 sites in U.S. Enrolled 951 Screen Failures: 771 (44.8) Not willing to participate 179 (23) IVRS noncompliance 104 (14) ≥3 CSBMs 91 (12) Safety Population 948 mITT population 946* Completed Treatment 738 (77.3) Withdrawal Reason: Adverse even

  8. Slide 8: Patient Demographics By Treatment Group

    Patient Demographics By Treatment Group Category Placebo Plecanatide n (%) Placebo N =234 0.3 mg N =237 1.0 mg N =238 3.0 mg N =237 Female Gender 209 (88.6) 203 (85.7) 202 (84.9) 205 (86.5) Mean Age (yr) (Min, Max) 46.2 (19, 75) 47.8 (20, 75) 47.1 (18, 75) 47.1 (18, 75) Race- White 171 (72.5) 171 (7

  9. Slide 9: Primary Endpoint Percent CSBM Responders

    Primary Endpoint Percent CSBM Responders % of Responders % of Responders *= p<0.05 ** = p<0.01 Plecanatide CIC Study

  10. Slide 10: Weekly Responder Rates

    Weekly Responder Rates ≥3 CSBMs/wk with an increase of ≥ 1 CSBM/wk * = p<0.05; ** = p < 0.01; *** = p < 0.001 Treatment Week % Responders *** Post-Treatment Plecanatide CIC Study

  11. Slide 11: Patients Reporting an Increase of ≥1 CSBM/week

    Patients Reporting an Increase of ≥ 1 CSBM/week % Responders ** *** ** = p < 0.01; *** = p < 0.001 Plecanatide CIC Study

  12. Slide 12: Time to First SBM & CSBM

    Time to First SBM & CSBM Time (Hours) * ** ** ** * = p<0.05; ** = p < 0.01; *** = p < 0.001 Percent of Patients Plecanatide CIC Study

  13. Slide 13: Stool Consistency Bristol Stool Form Scale Score

    Stool Consistency Bristol Stool Form Scale Score * = p<0.05; ** = p < 0.01; *** = p < 0.001 Treatment week ** ** 1 2 3 4 5 6 7 Plecanatide CIC Study

  14. Slide 14: Weekly Straining Scores

    Weekly Straining Scores Straining score based on 11-point score (0-10 rating) * = p<0.05; ** = p < 0.01; *** = p < 0.001 * Plecanatide CIC Study Mean Score

  15. Slide 15: Cumulative Days of Rescue Medication Use Per Month

    Cumulative Days of Rescue Medication Use Per Month Days Taking RM * = p<0.05; ** = p < 0.01; *** = p < 0.001 * Plecanatide CIC Study

  16. Slide 16: Global Assessments, Symptoms and QOL

    Global Assessments, Symptoms and QOL Severity *** ** *** * = p<0.05; ** = p < 0.01; *** = p < 0.001 Severe Moderate Mild None Moderate Mild Little bit Moderate Not Little Moderate Quite Mean Score Mean Score Severe Severe Plecanatide CIC Study Mean Score

  17. Slide 17: Treatment Emergent Adverse Events >2%

    Treatment Emergent Adverse Events >2% Event Placebo Plecanatide Adverse Event n (%) Placebo N=236 0.3 mg N=327 1.0 mg N=238 3.0 mg N=237 Any event 96 (40.7) 99 (41.8) 103 (43.3) 106 (44.7) Diarrhea 3 (1.3) 13 (5.5) 20 (8.4) 23 (9.7) Flatulence 5 (2.1) 5 (2.1) 3 (1.3) 14 (5.9) Abdominal Pain 11 (4.7)

  18. Slide 18: Summary of AEs and Diarrhea AEs

    Summary of AEs and Diarrhea AEs Event Placebo Plecanatide n (%) Placebo N=236 0.3 mg N=237 1.0 mg N=238 3.0 mg N=237 Serious AEs 5 (2.1) 1 (0.4) 1 (0.4) 2 (0.8) Treatment-emergent (TE) AEs 96 (40.7) 99 (41.8) 103 (43.3) 106 (44.7) AEs leading to withdrawal 8 (3.4) 9 (3.8) 16 (6.7) 13 (5.5) All Diarr

  19. Slide 19: Serious Adverse Events (SAEs)

    Serious Adverse Events (SAEs) Placebo Plecanatide Placebo n=5 0.3 mg n=1 1.0 mg n=1 3.0 mg n=2 Hypertension exacerbation Non-cardiac chest pain Endometriosis Acute cholecystitis Gastroenteritis Hypoaesthesia with weakness Spontaneous abortion Atypical chest pain Asthma exacerbation No signals in ser

  20. Slide 20: Conclusion

    Plecanatide 3.0 mg produced a statistically significant improvement in all primary and key secondary endpoints Clear dose-response with doses below 3 mg achieving statistical significance in some primary and key secondary endpoints Safe and well tolerated with a diarrhea rate at the highest dose bel

Synergy Pharmaceuticals — Technical Presentation (May 2013) on 6ix